drugset / Trial / NCT00778297

Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine

NCT00778297 ↗

RandomizedParallel-groupSingle-blindPrevention

Summary

This is a single blind, reference drug controlled, one center viral immunogenicity and tolerability study of FluvalAB FL-K-004 Trivalent Influenza Vaccine with 6 μg HA/strain/dos antigen content to assess immunogenicity and tolerability. The aim of the study is to assess the immunogenicity and tolerability of FluvalAB FL-K-004 trivalent influenza vaccine with 6 μg HA/strain/dos antigen content (study drug) in age groups 18-60 years and over 60 years, with the objective to verify efficacy and tolerability of the study drug according to CPMP/BWP/214/96: "Note for Guidance on Harmonization of Requirements for Influenza Vaccines", 12 March 1997.

Timeline

Start
2007-11
Primary completion
2008-01
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject FluvalAB FL-K-004 Vaccine 6 ug —
Comparator FluvalAB trivalent influenza vaccine Vaccine 15 ug —

Indications